Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Type 2 diabetes (diagnosed clinically) for minimum 24 weeks prior to randomisation
(visit 2)

- Current treatment with basal-only insulin (no prandial insulin) consisting of either
insulin detemir once daily (OD), insulin glargine OD or neutral protamine hagedorn
(NPH) insulin OD/twice daily (BID) for at least 12 weeks prior to randomisation
(visit 2), in combination with stable doses of OAD(s) (metformin, insulin
secretagogue (sulfonylurea or glinide), alpha-glucosidase inhibitor, pioglitazone or
dipeptidyl peptidase IV (DPP-IV) inhibitor in any approved (according to label) dose
or combination. Stable OAD doses are defined as unchanged doses for at least 12 weeks
prior to randomisation (visit 2)

- HbA1c (glycosylated haemoglobin) between 7.0-10.0% (both inclusive) by central
laboratory analysis

- Body mass index (BMI) below or equal to 45 kg/m^2

- Ability and willingness to adhere to the protocol including self-measured plasma
glucose (SMPG) according to the protocol

Exclusion Criteria:

- Treatment with rosiglitazone within the last 12 weeks prior to randomisation (visit
2)

- Treatment with glucagon like peptide-1 (GLP-1) receptor agonists within the last 12
weeks prior to randomisation (visit 2)

- Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the
last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial
physician)

- Previous participation in this trial. Participation is defined as randomised.
Re-screening is allowed once during the recruitment period

- Known or suspected hypersensitivity to trial products or related products

- The receipt of any investigational drug within 4 weeks prior to randomisation (visit
2)